Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: What we know, what we don't know, and what we need to know

Wiener Klinische Wochenschrift

Volumn 118, Issue 21-22, 2006, Pages 659-668

  Hunfeld, Klaus Peter ^a   Brade, Volker ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Antimicrobial agents; Antimicrobial resistance; Borrelia burgdorferi; In vitro susceptibility; Spirochetes; Susceptibility testing

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; AZTREONAM; CEFDINIR; CEFPODOXIME PROXETIL; CEFTIBUTEN; CEFTRIAXONE; CEFUROXIME; CETHROMYCIN; CHLORAMPHENICOL; DOXYCYCLINE; ERYTHROMYCIN; EVERNINOMICIN; FUSIDIC ACID; LINEZOLID; MACROLIDE; MEROPENEM; MEZLOCILLIN; NALIDIXIC ACID; PEFLOXACIN; PENICILLIN G; PIPERACILLIN; ROXITHROMYCIN; SPARFLOXACIN; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; BORRELIA BURGDORFERI; BORRELIA INFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IXODES RICINUS; LYME DISEASE; MINIMUM INHIBITORY CONCENTRATION; REVIEW; SYPHILIS; TREATMENT FAILURE;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BORRELIA BURGDORFERI GROUP; CALORIMETRY; CEFTRIAXONE; CEFUROXIME; DRUG RESISTANCE, BACTERIAL; ERYTHEMA CHRONICUM MIGRANS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SPECIES SPECIFICITY; TIME FACTORS;

EID: 33845683283     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-006-0693-z     Document Type: Review

References (87)

1. Steere AC (2001) Lyme disease. N Engl J Med 345: 115-112
2. CDC (2002) Lyme disease - United States 2000. Morb Mortal Wkly Rep 51: 29-31
3. O'Connell S, Granström M, Gray JS, Stanek G (1998) Epidemiology of European Lyme borreliosis. Zentralbl Bakteriol 287: 229-240
4. Stanek G, O'Connell S, Cimmino M, Aberer E, Kristoweritsch W, Granström M, Guy E, Gray J (1996) European Union concerted action on risk assessment in Lyme borreliosis: clinical case definitions for Lyme borreliosis. Wien Klin Wochenschr 108: 741-747
5. Hunfeld KP, Ruzic-Sabljic E, Norris DE, Kraiczy P, Strle F (2005) In vitro susceptibility testing of B. burgdorferi s.l. isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob Agents Chemother 49: 1294-1301
6. Svartz N (1941) Penicillin behandling vid dermatitis atrophicans Herxheimer. Nord Med 32: 2783
7. Thyresson N (1949) The penicillin treatment of acrodermatitis chronica atrophicans (Herxheimer). Acta Derm Venerol (Stockholm) 29: 572-621
8. Steere AC (1983) The spirochetal etiology of Lyme disease. N Engl J Med 308: 733-740
9. Oschmann P, Kaiser R (1999) Therapy and prognosis. In: Oschmann P, Kraiczy P, Halperin J, Brade V (eds) Lyme borreliosis and tick-borne encephalitis. UNI-Med Verlag AG, International Medical Publishers, Bremen, Germany, pp 112-119
10. Wormser GP, Nadelman RB, Dattwyler RJ, Dennis DT, Shapiro ED, Steere AC, Rush TJ, Rahn DW, Coyle PK, Persing DH, Fish D, Luft BJ (2000) Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin Infect Dis 31 [Suppl 1]: 1-14
11. Hunfeld KP, Kraiczy P, Kekoukh E, Schäfer V, Brade V (2002) Standardised in vitro susceptibility testing of Borrelia burgdorferi against well-known and newly developed antimicrobial agents - possible implications for new therapeutic approaches to Lyme disease. Int J Med Microbiol 291 [Suppl 33]: 125-137
12. Preac-Mursic V, Weber K, Pfister HW, Wilske B, Gross B, Baumann A, Prokop J (1989) Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection 17: 355-359
13. Hassler D, Zöller L, Haude M, Hufnagel HD, Heinrich F, Sonntag HG (1990) Cefotaxime versus penicillin in the late stage of Lyme disease - a prospective, randomized therapeutic study. Infection 18: 16-20
14. Pfister HW, Preac-Mursic V, Wilske B, Schielke E, Sorgel F, Einhaupl KM (1991) Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis 163: 311-318
15. Strle F, Preac-Mursic V, Cimperman J, Ruzic E, Maraspin V, Jereb M (1993) Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection 21: 83-88
16. Nowakowski J, McKenna D, Nadelman RB, Cooper D, Bittker S, Holmgren D, Pavia C, Johnson RC, Wormser GP (2000) Failure of treatment with cephalexin for Lyme disease. Arch Fam Med 9: 563-567
17. Dever LL, Jorgensen JH, Barbour AG (1992) In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies. J Clin Microbiol 30: 2692-2697
18. Boerner J, Failing K, Wittenbrink MM (1995) In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: influence of test conditions on minimal inhibitory concentration (MIC) values. Zentralbl Bakteriol 283: 49-60
19. Johnson RC, Kodner CB, Jurkovich PJ, Collins JJ (1991) Comparative in vitro and in vivo susceptibility of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob Agents Chemother 34: 2133-2136
20. Johnson RC, Schmid FW, Hyde FW, Steigerwalt AG, Brenner DJ (1984) Borrelia burgdorferi sp. nov.: etiological agent of Lyme disease. Int J Syst Bacteriol 34: 596-597
21. Berger BW, Kaplan MH, Rothenberg IR, Barbour AG (1985) Isolation and characterisation of the Lyme disease spirochete from the skin of patients with erythema chronicum migrans. J Am Acad Dermatol 13: 444-449
22. Luft BJ, Volkman DJ, Halperin JJ, Dattwyler RJ (1988) New chemotherapeutic approaches in the treatment of Lyme borreliosis. Ann N Y Acad Sci 539: 352-361
23. Levin JM, Nelson JA, Segreti J, Harrison B, Benson CA, Strle F (1993) In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents. Antimicrob Agents Chemother 37: 1444-1446
24. Preac-Mursic V, Wilske B, Schierz G (1986) European Borrelia burgdorferi isolated from humans and ticks: culture conditions and antibiotic susceptibility. Zentralbl Bakteriol Hyg 263: 112-118
25. Boerner J (1994) Empfindlichkeitsprüfung von Borrelia burgdorferi gegen Antibiotika und Chemotherapeutika. Inauguraldissertation, Justus-Liebig Universität, Gießen
26. Reisinger EC, Wendelin I, Gasser R (1995) Inactivation of diaminopyrimidines and sulfonamides in Barbour-Stoenner-Kelly medium for isolation of Borrelia burgdorferi. Eur J Clin Microbiol Infect Dis 14: 732-733
27. Sohaskey CD, Barbour AG (1999) Esterases in serum-containing growth media counteract chloramphenicol acetyltransferase activity in vitro. Antimicrob Agents Chemother 43: 655-660
28. Karlsson M, Hammers S, Nilsson-Ehle I, Malmborg AS, Wretlind B (1992) Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicrob Agents Chemother 40: 1104-1107
29. Hunfeld KP, Kraiczy P, Wichelhaus TA, Schäfer V, Brade V (2000) New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances. Eur J Clin Microbiol Infect Dis 19: 27-32
30. Preac-Mursic V, Wilske B, Schierz G, Holmburger M, Suss E (1987) In vitro susceptibility of Borrelia burgdorferi. Eur J Clin Microbiol Infect Dis 6: 424-426
31. Alder J, Mitten M, Jarvis K, Gupta P, Clement J (1993) Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo. Antimicrob Agents Chemother 37: 1329-1333
32. Reisinger EC, Wendelin I, Gasser R, Halwachs G, Wilders-Truschnig M, Krejs G (1996) Antibiotics and increased temperature against Borrelia burgdorferi in vitro. Scand J Infect Dis 28: 155-157
33. Baradaran-Dilmaghani R, Stanek G (1996) In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. Infection 24: 60-63
34. Hunfeld KP, Kraiczy P, Wichelhaus TA, Schäfer V, Brade V (2000) Colorimetric in vitro susceptibility testing of penicillins, cephalosporines, macrolides, streptogramins, tetracyclines and aminoglycosides against Borrelia burgdorferi isolates. Int J Antimicrob Agents 15: 11-17
35. Hunfeld KP, Weigand J, Wichelhaus TA, Kekoukh E, Kraiczy P, Brade V (2001) In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin, and fusidic acid against Borrelia burgdorferi isolates. Intern J Antimicrob Agent 17: 203-208
36. Hunfeld KP (2004) Contributions to seroepidemiology, diagnosis, and antimicrobial susceptibility of Borrelia, Ehrlichia, and Babesia as indigenous tick-conducted pathogens. Shaker Verlag GmbH, Aachen, pp 91-118
37. Dever LL, Jorgensen JH, Barbour AG (1993) In vitro activity of vancomycin against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother 37: 1115-1121
38. Dever LL, Torigian CV, Barbour AG (1999) In vitro activities of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi. Antimicrob Agents Chemother 43: 1773-1775
39. Hunfeld KP, Rödel R, Wichelhaus TA (2003) In vitro activity of eight oral cephalosporins against B. burgdorferi. Intern J Antimicrob Agents 21: 313-318
40. Kaiczy P, Weigand J, Wichelhaus TA, Heisig P, Backes H, Schäfer V, Acker G, Brade V, Hunfeld KP (2001) In vitro activity of fluoroquinolones against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother 45: 2486-2494
41. Knight SW Samuels DS (1999) Natural synthesis of a DNA-binding protein from the C-terminal domain of DNA gyrase A in Borrelia burgdorferi. EMBO J 18: 4875-4881
42. Johnson RC (1989) Isolation techniques for spirochetes and their sensitivity to antibiotics in vivo and in vitro. Rev Infect Dis 11 [Suppl 6]: S1505-S1510
43. Lakos A, Nagy G (1999) Effect of an antibiotic combination on the propagation of Borrelia burgdorferi, causative agent of Lyme disease. Orv Hetil 140: 1529-1532
44. Murgia R, Marchetti F, Cinco M (1999) Comparative bacteriostatic and bactericidal activities of cefozidime against Borrelia burgdorferi s.l. Antimicrob Agents Chemother 43: 3030-3032
45. Samuels DS, Garon CF (1993) Coumermycin A1 inhibits growth and induces relaxation of supercoiled plasmids in B. burgdorferi, the Lyme disease agent. Antimicrob Agents Chemother 37: 46-50
46. Galbraith KM, Ng AC, Eggers BJ, Kuchel CR, Eggers CH, Samuels DS (2005) parC mutations in fluoroquinolone-resistant Borrelia burgdorferi. Antimicrob Agents Chemother 49: 4354-4357
47. Morrissey I, George JT (2000) Purification of pneumococcal type II topoisomerase and inhibition by gemifloxacin and other quinolones. J Antimicrob Chemother 45 [Suppl S1]: 101-106
48. Lewin CS, Morrissey I, Smith JT (1992) The bactericidal activity of sparfloxacin. J Antimicrob Chemother 30: 625-632
49. Capobianco JO, Cao Z, Shortrige VD, Ma Z, Flamm RK, Zhong P (2000) Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Str. pneumoniae. Antimicrob Agents Chemother 44: 1562-1567
50. Balfour JA, Figgitt DP (2001) Telithromycin. Drugs 61: 815-829
51. Dougherty TJ, Barrett JF (2001) ABT-773: a new ketolide antibiotic. Expert Opin Investig Drugs 10: 343-351
52. Hunfeld KP, Kekoukh E, Wichelhaus TA, Kraiczy P, Brade V (2001) In vitro susceptibility of the Borrelia burgdorferi s.l. complex to ABT 773 - a novel ketolide. J Antimicrob Chemotherapy 48: 441-449
53. Hunfeld KP, Wichelhaus TA, Rödel R, Acker G, Brade V, Kraiczy P (2004) Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother 48: 344-347
54. Preac-Mursic V, Marget W, Busch U, Pleterski-Riegler D, Hagel S (1996) Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis. Infection 24: 9-16
55. Yassin HM, Dever LL (2001) Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections. Expert Opin Investig Drugs 10: 353-367
56. Terekhova D, Sartakova ML, Wormser GP, Schwartz I, Cabello FC (2002) Erythromycin resistance in B. burgdorferi. Antimicrob Agents Chemother 46: 3637-3640
57. Hansen K, Hovmark A, Lebech AM, Lebech K, Olsson I, Halkier-Sorensen LL, Olsson E, Asbrink E (1992) Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Dermatologica Venerologica 72: 297-300
58. rd edn. McGraw-Hill, New York
59. Fujita K, Baba T, Isono K (1998) Genomic analysis of the genes encoding ribosomal proteins in eight eubacterial species and Saccharomyces cerevisiae. Genome Inform Ser Workshop Genome Inform 9: 3-12
60. Van Dam AP, Kuiper H, Vos K, Widjojokusumo A, Spanjaard L, De Jongh BM, Ramselaar ACP, Kramer MD, Dankert J (1997) Different genospecies of B. burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clin Infect Dis 17: 708
61. Peter O, Bretz AG (1994) In vitro susceptibility of B. burgdorferi, B. garinii and B. afzelii to 7 antimicrobial agents. In: Cevenini R, Sambri V, La Placa M (eds) Advances in Lyme borreliosis research. Societa Editrice Esculapio, Bologna, pp 167-170
62. Sicklinger M, Wienecke R, Neubert U (2003) In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: A comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto. J Clin Microbiol 41: 1791-1793
63. Wilske B, Zoeller L, Brade V, Eiffert H, Goebel UB, Stanek G, Pfister HW (2000) Lyme-Borreliose. In: Mauch H, Gaterman S (eds) Qualitätsstandards in der Mikrobiologisch-infektiologischen Diagnostik. Urban & Fischer, München
64. Ruzic-Sabljic E, Podreka T, Maraspin V, Strle F (2005) Susceptibility of Borrelia afzelii strains to antimicrobial agents. Int J Antimicrob Agents 25: 474-778
65. Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, Parenti DL, Holman MS, Persing DH, Steere AC (2002) Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med 136: 421-428
66. Thanassi WT, Schoen RT (2000) The Lyme disease vaccine: conception, development, and implementation. Ann Intern Med 132: 661-668
67. Panconesi E, Zuccati G, Cantin A (1981) Treatment of syphilis: a short critical review. Sex Transm Dis 8: 321-325
68. Viljanen MK, Oksi J, Salomaa P, Skurnik M, Peltonen R, Kalimo H (1992) Cultivation of Borrelia burgdorferi from the blood and a subcutaneous lesion of a patient with relapsing febrile nodular nonsuppurative panniculitis. J Infect Dis 165: 596-597
69. Wormser GP, Ramanathan R, Nowakowski J, McKenna D, Holmgren D, Visintainer P, Dornbush R, Singh B, Nadelman RB (2003) Duration of antibiotic therapy for early Lyme disease. Ann Intern Med 138: 697-704
70. Strle F, Maraspin V, Lotric-Furlan S, Ruzic-Sabljic E, Cimperman J (1996) Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. Infection 24: 64-68
71. Straubinger RK, Summers BA, Chang YF, Appel MJG (1997) Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J Clin Microbiol 35: 111-116
72. Oksi J, Marjamaki M, Nikoskelainen J, Viljanen MK (1999) Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis. Ann Med 31: 225-232
73. Lomholt H, Lebech AM, Hansen K, Brandrup F, Halkier-Sorensen L (2000) Long-term serological follow-up of patients treated for chronic cutaneous borreliosis or culture-positive erythema migrans. Acta Derm Venereol 80: 362-366
74. Criswell D, Tobiason VL, Lodmell JS, Samuels DS (2006) Mutations conferring aminoglycoside and spectinomycin resistance in B. burgdorferi. Antimicrob Agents Chemother 50: 445-452
75. Lukehart SA, Godornes C, Molini BJ, Sonnett P, Hopkins S, Mulcahy F, Engelman J, Mitchell SJ, Rompalo AM, Marra CM, Klausner JD (2004) Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med 351: 154-158
76. Breier F, Khanakah G, Stanek G, Kunz G, Aberer E, Schmidt B, Tappeiner G (2001) Isolation and polymerase chain reaction typing of Borrelia afzelii from a skin lesion in a seronegative patient with generalized ulcerating bullous lichen sclerosus et atrophicus. Br J Dermatol 144: 387-392
77. Aberer E, Kersten A, Klade H, Poitschek C, Jurecka W (1996) Heterogeneity of Borrelia burgdorferi in the skin. Am J Dermatopathol 18: 571-579
78. Pachner AR, Basta J, Delaney E, Hulinska D (1995) Localization of Borrelia burgdorferi in murine Lyme borreliosis by electron microscopy. Am J Trop Med Hyg 52: 128-133
79. Brorson O, Brorson SH (1997) Transformation of cystic forms of Borrelia burgdorferi to normal, mobile spirochetes. Infection 25: 240-246
80. Brouqui P, Badiaga S, Raoult D (1996) Eucaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin. Antimicrob Agents Chemother 40: 1552-1554
81. Comstock LE, Thomas DD (1989) Penetration of endothelial cell monolayers by Borrelia burgdorferi. Infect Immun 57: 1626-1628
82. Ma Y, Sturrock A, Weis JJ (1991) Intracellular localisation of B. burgdorferi within endothelial cells. Infect Immun 59: 671-678
83. Strle F, Nelson JA, Ruzic-Sabljic E, Cimperman J, Maraspin V, Lotric-Furlan S, Cheng Y, Picken MM, Trenholme GM, Picken RN (1996) European Lyme borreliosis: 231 culture-confirmed cases involving patients with erythema migrans. Clin Infect Dis 23: 61-65
84. Schwartz I, Wormser GP, Schwartz JJ, Cooper D, Weissensee P, Gazumyan A, Zimmermann E, Goldberg NS, Bittker S, Campbell GL, Pavia CS (1992) Diagnosis of early Lyme disease by polymerase chain reaction amplification and culture of skin biopsies from erythema migrans lesions. J Clin Microbiol 30: 3082-3088
85. Zore A, Ruzic-Sabljic E, Maraspin V, Cimperman J, Lotric-Furlan S, Pikelj A, Jurca T, Logar M, Strle F (2002) Sensitivity of culture and polymerase chain reaction for the etiologic diagnosis of erythema migrans. Wien Klin Wochenschr 114: 606-609
86. Logar M, Lotric-Furlan S, Maraspin V, Cimperman J, Jurca T, Ruzic-Sabljic E, Strle F (1999) Has the presence or absence of Borrelia burgdorferi sensu lato as detected by skin culture any influence on the course of erythema migrans? Wien Klin Wochenschr 111: 945-950
87. Hunfeld KP, Ruzic-Sabljic E, Norris DE, Kraiczy P, Strle F (2006) Risk of culture confirmed borrelial persistence in patients treated for erythema migrans and possible mechanisms of resistance. Int J Med Microbiol 296 [Suppl 40]: 233-241